PATT MORRISON SCHEDULE
Thursday, January 6, 2011
CALL-IN @ 866-893-5722, 866-893-KPCC; OR JOIN THE CONVERSATION ONLINE ON THE PATT MORRISON BLOG AT KPCC-DOT-ORG
DAVID LAZARUS FILLS-IN FOR PATT
1:06 – 1:39
1:41 – 1:58:30
South Sudan votes,
On January 9th there will be a vote in an African country that will have ramifications across the continent and the entire globe.
Lako Tongun, professor of international & intercultural studies & political studies at
- Aside from teaching about Sudanese politics, history & culture, Tongun is from South Sudan—he fled the country during the first civil war but has returned several times. He is voting in the election on Jan. 9th.
Amir Idris, associate professor of African studies at
2:06 – 2:30
FDA withdraws approval of Avastin cancer drug over outcries
What happens when a pharmaceutical drug works, but the side effects are also devastating? That’s the question the Food and Drug Administration is weighing as it considers what to do about Avastin, the widely popular anti-cancer drug, which has produced widely varied results—shrinking tumors in some patients and causing severe damage to vital organs in others. The FDA last month announced it was withdrawing approval of the drug for treatment of late stage breast cancer. Doctors can still choose to prescribe it off-label, since it remains approved for treatment of colon, lung, brain and kidney cancers, but Medicare and private insurance carriers who use FDA approval to guide their coverage policies may decide against paying for it. At about $8,000 a month, it’s unlikely many patients could afford it on their own. Meanwhile, Avastin’s fate has already divided the breast cancer advocacy community—pitting Susan G. Komen for the Cure against other leading groups like the National Breast Cancer Coalition, which applauds the decision. How does the FDA weigh the benefits and risks of a drug before approval and one it’s on the market and should it deny approval for risky, expensive treatments?
Dr. Susan Love, President and founder of the Dr. Susan Love Research Foundation and Clinical Professor of Surgery at UCLA’s David Geffen School of Medicine
CALL HER @
2:30 – 2:58:30
4G wireless networks—more of a marketing than a technological breakthrough?
If you own a smart phone you already know that your gadget is only as good as the network that supports it—ask any frustrated iPhone owner who has to deal with the occasionally unreliable speeds and connectivity of AT&T’s wireless network. So while carriers roll out new & improved “4G” high speed broadband networks consumers should be asking what they’re really getting from networks that are supposed to be faster and will certainly be more expensive. AT&T flipped the switch on its new 4G network yesterday, the only problem being that all they did was change the name of its existing 3G system. Sprint was the first carrier to offer 4G service but it’s spotty at best; and Verizon is already marketing a network that’s supposed to be faster than 4G, without perfecting or even fully implementing their own 4G approach. While it all sounds great, how is a cell phone consumer supposed to know exactly what they’re getting for their money?
Representative of the International Telecommunication
Producer, Patt Morrison Program
NPR Affiliate for
89.3 KPCC-FM | 89.1 KUOR-FM | 90.3 KPCV-FM